Carmat (ALCAR) EUR0.04

Sell:€0.89Buy:€0.89€0.00 (0.34%)

Prices delayed by at least 15 minutes
Sell:€0.89
Buy:€0.89
Change:€0.00 (0.34%)
Prices delayed by at least 15 minutes
Sell:€0.89
Buy:€0.89
Change:€0.00 (0.34%)
Prices delayed by at least 15 minutes

Company Information

About this company

Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Key people

Stephane Piat
Chief Executive Officer, Director
Pascale D'Arbonneau
Chief Financial Officer
Raouia Bouyanzer
Human Resources Director
Francesco Arecchi
Global Market Development Director
Thierry Dupoux
Quality Assurance and Regulatory Affairs Director
Alexandre Eleonore
Manufacturing Director
Marc Grimme
Research and Development Director
Christian Latremouille
Director of Surgical Affairs
Pierre Bastid
Independent Chairman of the Board
David Coti
Director
Karl Hennessee
Director - Representative of Matra Defense
Florent Battistella
Independent Director
John B. Hernandez
Independent Director
Click to see more

Key facts

  • EPIC
    ALCAR
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • ISIN
    FR0010907956
  • Market cap
    €50.59m
  • Employees
    162
  • Shares in issue
    35.15m
  • Exchange
    Euronext Paris
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.